All
Chamomile and Honey are More Than Teatime Fare
May 5th 2015The concerns a family might have when a loved one develops squamous cell carcinoma of the oral cavity might seem obvious: fear that the patient will have a shorter life due to advanced disease, empathy for her pain, and a feeling of isolation in facing a rare presentation of cancer.
Clinical Trial Awareness, Enrollment Increasing
May 5th 2015While clinical trials remain a treatment option and play a significant role in furthering cancer research in treatment, symptom management and survivorship, less than 5 percent of patients participate in them, and 40 percent of patients report that they do not understand the idea of a clinical trial.
Making Progress in the Treatment of Ovarian Cancer
May 2nd 2015While surgical advances and new treatment approvals, including Lynparza and Avastin, have improved the outlook in ovarian cancer, late diagnosis and tumor resistance remain as significant barriers to major progress in treating the disease.
FDA Grants Priority Review to Adcetris Consolidation in Hodgkin Lymphoma
April 22nd 2015The FDA has granted a priority review to the antibody-drug conjugate Adcetris as a consolidation therapy following autologous stem cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression.
Xalkori Granted Breakthrough Designation for ROS1-Positive Lung Cancer
April 21st 2015The Food and Drug Administration has granted a breakthrough therapy designation to Xalkori (crizotinib) as a potential treatment for patients with ROS1-positive non–small cell lung cancer, based on phase 1 findings published in the New England Journal of Medicine.
Long-Term Aspirin Use Decreases Risk of Gastrointestinal Cancers, Especially Colorectal
April 20th 2015A recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.
Early Phase Study Shows MM-302 Has Activity in Heavily-Pretreated HER2-Positive Breast Cancer
April 20th 2015MM-302, a novel antibody-drug conjugate that specifically targets cancer cells overexpressing the HER2 receptor, showed signs of clinical activity in heavily pretreated patients with metastatic, HER2-positive breast cancer.